



Divya Parikh, MD

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **VA Palo Alto Health Care System Dept of Medical Oncology**

3801 Miranda Ave

Palo Alto, CA 94304

Tel (650) 617-2732

Fax (650) 614-8473

Bio

BIO

Dr. Divya Parikh is board-certified in both medical oncology and internal medicine. She obtained her medical degree from Boston University School of Medicine and completed both her residency and fellowship through Stanford University. During her fellowship, she simultaneously earned a Master of Science in health policy from Stanford University.

Dr. Parikh specializes in the care of patients with genitourinary cancers. In addition to her clinical responsibilities, she currently is a clinical assistant professor of medical oncology at Stanford School of Medicine. She mentors medical residents and fellows by sharing her insights, knowledge, and expertise.

Dr. Parikh has a strong research background. She has published in multiple academic journals and presented her findings through poster and oral presentations at various medical conferences.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2021)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2021) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2018)
- Residency: Stanford University Internal Medicine Residency (2018) CA
- Medical Education: Boston University School of Medicine (2015) MA

Publications

PUBLICATIONS

- **Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.** *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., Srinivas, S., Fan, A. C., Shah, S., Patel, M. I.
2024; 32 (3): 161
- **Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.**
Khaki, A., Fan, A. C., Shah, S., Parikh, D., Chien, J., Moore, K., Ruiz, S., Haas, D., Fakhoury, L., Del Toro, N., Baker, P., O'Brien, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
- **Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.** *Breast cancer research and treatment*
Parikh, D. A., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., Karin, M. R., Wapnir, I. L., Patel, M. I., Sledge, G. W., Caswell-Jin, J. L.
2022
- **Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study** *EUROPEAN UROLOGY*
Parikh, D. A., Kaki, A., Williams, S. B.
2022; 81 (4): 429-430
- **Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.**
Golla, V., Shan, Y., Farran, E., Vu, K., Stewart, C. A., Khaki, A., Keegan, K. A., Kamat, A. M., Tyler, D. S., Freedland, S. J., Williams, S. B.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.** *European urology*
Parikh, D. A., Khaki, A. R., Williams, S. B.
2022
- **Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.** *Urologic oncology*
Golla, V., Shan, Y., Farran, E. J., Stewart, C. A., Vu, K., Yu, A., Khaki, A. R., Parikh, D. A., Swanson, T. A., Keegan, K. A., Kamat, A. M., Tyler, D. S., Freedland, et al
2022
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Coaches Activating Reaching and Engaging Patients (CAREPlan): A randomized controlled trial combining two evidence-based interventions to improve goals of care documentation**
Parikh, D., Asuncion, M., Hansen, J., Seevaratnam, B., Khateeb, S., Rosenthal, E., Teuteberg, W., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Evolving oncology provider perspectives on care delivery during the COVID-19 pandemic.**
Parikh, D., Ragavan, M., Srinivas, S., Garrigues, S., Rosenthal, E., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems.** *JCO oncology practice*
Parikh, D. A., Ragavan, M., Dutta, R., Garnet Edwards, J., Dickerson, J., Maitra, D., Aggarwal, S., Lee, F., Patel, M. I.
2021: OP2000890

- **Addressing financial toxicity in urologic oncology patients.**
Parikh, D., Srinivas, S., Kerr, E., Patel, M.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Defining the clinician's role in mitigating financial toxicity: an exploratory study.** *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*
Ragavan, M., Parikh, D., Patel, M.
2021
- **Understanding patient perspectives on window of opportunity clinical trials.**
Parikh, D., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., Sledge, G. W., Caswell-Jin, J.
AMER SOC CLINICAL ONCOLOGY.2020
- **Comparison of perspectives and practices to mitigate financial toxicity between advance practice providers and attending oncologists.**
Ragavan, M., Parikh, D., Patel, M.
AMER SOC CLINICAL ONCOLOGY.2020
- **Healthcare delivery interventions to reduce cancer disparities worldwide.** *World journal of clinical oncology*
Dickerson, J. C., Ragavan, M. V., Parikh, D. A., Patel, M. I.
2020; 11 (9): 705–22
- **Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.**
Parikh, D., Serrato, P., Srinivas, S., Ryckman, T., Salomon, J., Goldhaber-Fiebert, J. D.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Health Disparities in Germline Genetic Testing for Cancer Susceptibility** *Current Breast Cancer Reports*
Parikh, D. A., Dickerson, J. C., Kurian, A. W.
2020
- **Financial toxicity among veterans with cancer.**
Parikh, D., Ragavan, M., Khateeb, S., Patel, M. I.
AMER SOC CLINICAL ONCOLOGY.2019
- **Perspectives and practices of oncology providers in addressing financial toxicity.**
Ragavan, M., Parikh, D., Patel, M. I.
AMER SOC CLINICAL ONCOLOGY.2019
- **Demographic factors associated with financial toxicity: Results from the multisite cost study.**
Parikh, D., Ragavan, M., Dutta, R., Edwards, J., Maitra, D., Patel, M. I.
AMER SOC CLINICAL ONCOLOGY.2019
- **To Take or Not to Take a Side: That Is the Question.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Parikh, D. A., Lin, A. Y.
2019: JCO1801767
- **Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository.** *Journal of oncology practice*
Parikh, D. A., Walia, G. n., Freeman-Daily, J. n., Hennink, M. n., Tomalia, T. n., Buonanno, L. n., Goldman, L. n., Addario, B. n., Patel, M. I.
2019: JOP1900135
- **Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?** *JCO precision oncology*
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
2018; 2: 1-10
- **Financial toxicity of cancer treatment at a diverse county hospital.**
Parikh, D., Ragavan, M., Maitra, D., Aggarwal, S., Patel, M. I.
AMER SOC CLINICAL ONCOLOGY.2018
- **Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?** *JCO Precision Oncology*
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.

2018

- **Impact of patient demographics, tumor characteristics, and treatment type on treatment delay throughout breast cancer care at a diverse academic medical center.** *International journal of women's health*
Khanna, S., Kim, K. N., Qureshi, M. M., Agarwal, A., Parikh, D., Ko, N. Y., Rand, A. E., Hirsch, A. E.
2017; 9: 887-896
- **Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?**
Hall, E., Parikh, D., Gupta, T., Caswell, J., Mills, M., Kingham, K., Koff, R., Ford, J. M., Kurian, A. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Race/Ethnicity, Primary Language, and Income Are Not Demographic Drivers of Mortality in Breast Cancer Patients at a Diverse Safety Net Academic Medical Center.** *International journal of breast cancer*
Parikh, D. A., Chudasama, R., Agarwal, A., Rand, A., Qureshi, M. M., Ngo, T., Hirsch, A. E.
2015; 2015: 835074
- **Patient demographic characteristics and disease stage as drivers of disparities in mortality in prostate cancer patients who receive care at a safety net academic medical center.** *Clinical genitourinary cancer*
Rand, A. E., Agarwal, A., Ahuja, D., Ngo, T., Qureshi, M. M., Gupta, A., Hirsch, A. E.
2014; 12 (6): 455-60
- **Devising the optimal preclinical oncology curriculum for undergraduate medical students in the United States.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
DeNunzio, N. J., Joseph, L., Handal, R., Agarwal, A., Ahuja, D., Hirsch, A. E.
2013; 28 (2): 228-36